SERVICE

Online Inquiry

For Lab Research Use Only, Not for Human or Animal Therapeutic Use.

  • Verification code
    Click image to refresh the verification code.

Custom Antibody Design Service for RNAi


Owing to their superior stability and specificity, monoclonal antibodies have attracted more and more attention as a powerful tool for targeted delivery for RNA interference (RNAi). Scientists from Creative Biolabs have accumulated rich experience in antibody development and antibody-mediated delivery system for RNAi. We have developed an efficient method for antibody short dsRNA conjugation, no need to consider the bounds of genetic fusion.

Antibody-mediated Small Interfering RNA (siRNA) Delivery System

Previous studies have shown that systemic distribution of siRNA often requires very high doses which leads to its unintended distribution and side effects. To become better in in vivo RNAi therapeutics, the development of targeted delivery methods is required. Targeting siRNA to specific cell types can be realized by antibodies using affinity reagents. This strategy improves cell penetration, effectively sequesters siRNA from the plasma matrix and prevents nuclease degradation, and increases the size of the siRNA complex, preventing kidney excretion or removal by the reticuloendothelial system. Therefore, this not only satisfies the needed delivery improvements but also addresses all the primary causes of poor siRNA bioavailability.

Antibody-targeted nanoparticle formation and intracellular siRNA delivery. Figure 1. Antibody-targeted nanoparticle formation and intracellular siRNA delivery. (Palanca-Wessels, 2016)

Service

With Ph.D. level scientists and over a decade of experience in antibody development, Creative Biolabs is dedicated to helping our clients prepare monoclonal antibodies against various targets. Using antibodies against various receptors, our scientists have developed a versatile method for antibody short dsRNA (such as siRNA, miRNA, ssRNA) conjugation that is not limited by the bounds of genetic fusion. The complex can be intravenously administered to in vivo models and taken up by specific cells via endocytosis. Using this strategy, we have developed a method that allows any available antibody to be conjugated to siRNA for delivery purposes.

Highlights

Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in antibody development and antibody-mediated delivery system for RNAi. We are confident in providing clients with the best service at the most competitive cost. Please contact us for more information and a detailed quote.

Reference

  1. Palanca-Wessels, M.C.; et al. (2016). Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget. 7(8):9561.

For Lab Research Use Only, Not for Human or Animal Therapeutic Use.

Interested in our expertise?

Contact us for more information

Get free consultations

USA

  • Tel:
  • Email:

Europe

Easy access to products and services you need from our library via powerful searching tools

Enter your email here to subscribe.

Submit

Follow us on

For Lab Research Use Only, Not for Human or Animal Therapeutic Use.

Copyright © 2021 Creative Biolabs. All Rights Reserved.